Rx Product Updates (January 2017)

Pharmacy Times, January 2017 Oncology, Volume 83, Issue 1

Read about the new Rx products featured in January.

Marketed By: Boehringer Ingelheim

Indication: The FDA approved a new indication for Jardiance (empagliflozin) to reduce the risk of cardiovascular death in adult patients with type 2 diabetes and cardiovascular diseases.

Dosage Form: Tablets: 10 and 25 mg

For More Information: jardiance.com

Taytulla

Marketed By: Allergan

Indication: Allergan has announced the availability of Taytulla (norethindrone acetate and ethinyl estradiol capsules and ferrous fumarate capsules) as the first and only oral contraceptive in a softgel capsule for the prevention of pregnancy.

Dosage Form: Capsules: 1 mg/20 mcg

For More Information: Taytulla.com

Opdivo

Marketed By: Bristol-Myers Squibb

Indication: The FDA has approved Opdivo (nivolumab) injection, for intravenous use, for the treatment of patients with recurrent or metastatic squamous cell carcinoma of the head and neck with disease progression on or after platinum-based therapy.

Dosage Form: Injection: 40-mg/4- mL and 100-mg/10-mL solution in a single-dose vial

For More Information: opdivo.com

Restasis Multidose

Marketed By: Allergan

Indication: The FDA has approved Restasis Multidose (cyclosporine ophthalmic emulsion) 0.05% prescription treatment to help patients with a type of chronic dry eye to make more of their own tears.

Dosage Form: Eyedrops: 0.5 mg/mL

For More Information: allergan.com